Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
EGRX

EGRX - Eagle Pharmaceuticals Inc-DE Stock Price, Fair Value and News

4.15USD+0.08 (+1.97%)Delayed

Market Summary

EGRX
USD4.15+0.08
Delayed
1.97%

EGRX Stock Price

View Fullscreen

EGRX RSI Chart

EGRX Valuation

Market Cap

76.0M

Price/Earnings (Trailing)

5.78

Price/Sales (Trailing)

0.27

EV/EBITDA

3.23

Price/Free Cashflow

-7.36

EGRX Price/Sales (Trailing)

EGRX Profitability

Free Cashflow Yield

-13.59%

EGRX Fundamentals

EGRX Revenue

EGRX Earnings

Breaking Down EGRX Revenue

Last 7 days

7.8%

Last 30 days

8.9%

Last 90 days

-17.8%

Trailing 12 Months

-79.2%

How does EGRX drawdown profile look like?

EGRX Financial Health

EGRX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023267.0M257.6M00
2022246.2M272.2M298.2M316.6M
2021183.0M189.2M179.1M171.5M
2020192.1M177.4M186.1M187.8M
2019216.5M213.9M203.7M195.9M
2018206.5M215.7M204.0M213.3M
2017236.7M245.9M271.1M236.7M
201659.5M94.4M126.5M189.5M
201550.5M50.7M53.6M66.2M
201420.2M20.9M19.1M19.2M
20136.3M10.0M13.7M17.7M
2012002.5M0

Tracking the Latest Insider Buys and Sells of Eagle Pharmaceuticals Inc-DE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 28, 2024
tarriff scott
sold (taxes)
-13,286
6.27
-2,119
-
Feb 27, 2024
tarriff scott
sold (taxes)
-20,311
6.44
-3,154
-
Feb 27, 2024
tarriff scott
acquired
-
-
12,950
-
Feb 27, 2024
cahill brian joseph
sold (taxes)
-10,233
6.44
-1,589
chief financial officer
Feb 27, 2024
cahill brian joseph
acquired
-
-
3,800
chief financial officer
Feb 02, 2024
cahill brian joseph
sold (taxes)
-5,463
5.85
-934
chief financial officer
Jan 05, 2024
tarriff scott
sold (taxes)
-22,171
5.13
-4,322
-
Jan 05, 2024
cahill brian joseph
sold (taxes)
-3,770
5.13
-735
chief financial officer
Dec 18, 2023
cahill brian joseph
sold (taxes)
-2,151
4.76
-452
chief financial officer
Nov 02, 2023
tarriff scott
sold
-148,326
13.87
-10,694
ceo

1–10 of 50

Which funds bought or sold EGRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-123,564
-
-%
May 16, 2024
COMERICA BANK
sold off
-100
-2,568
-
-%
May 16, 2024
Virtus Investment Advisers, Inc.
sold off
-100
-109,134
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.93
-3,457
5,450
-%
May 15, 2024
Aristides Capital LLC
sold off
-100
-86,039
-
-%
May 15, 2024
PDT Partners, LLC
new
-
141,784
141,784
0.01%
May 15, 2024
AQR CAPITAL MANAGEMENT LLC
added
78.07
2,024,480
4,606,340
0.01%
May 15, 2024
Cubist Systematic Strategies, LLC
sold off
-100
-79,642
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-48.14
-17,188
18,591
-%
May 15, 2024
Engineers Gate Manager LP
sold off
-100
-72,812
-
-%

1–10 of 48

Are Funds Buying or Selling EGRX?

Are funds buying EGRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EGRX
No. of Funds

Unveiling Eagle Pharmaceuticals Inc-DE's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 18, 2024
tarriff scott
17.6%
2,470,570
SC 13G/A
Feb 14, 2024
graves michael
1.8%
238,660
SC 13D
Feb 13, 2024
janus henderson group plc
6.0%
775,525
SC 13G/A
Feb 13, 2024
vanguard group inc
4.91%
638,124
SC 13G/A
Feb 12, 2024
brandes investment partners, lp
5.74%
745,079
SC 13G
Feb 07, 2024
hirschman orin
8.2%
1,061,509
SC 13G
Jan 26, 2024
blackrock inc.
7.6%
984,075
SC 13G/A
Jan 22, 2024
state street corp
1.71%
222,594
SC 13G/A
Jul 07, 2023
blackrock inc.
7.7%
1,009,090
SC 13G/A
Feb 14, 2023
tarriff scott
18.06%
2,533,457
SC 13G/A

Recent SEC filings of Eagle Pharmaceuticals Inc-DE

View All Filings
Date Filed Form Type Document
May 29, 2024
8-K
Current Report
May 22, 2024
8-K
Current Report
May 15, 2024
8-K
Current Report
May 10, 2024
NT 10-Q
NT 10-Q
Apr 12, 2024
8-K
Current Report
Mar 18, 2024
SC 13G/A
Major Ownership Report
Mar 18, 2024
NT 10-K
NT 10-K

Peers (Alternatives to Eagle Pharmaceuticals Inc-DE)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
357.9B
85.6B
-3.11% -10.20%
9.3
4.18
5.68% 202.39%
330.7B
61.4B
-0.40% 14.82%
143.41
5.39
6.11% -82.30%
165.3B
29.5B
-0.40% 34.19%
43.93
5.6
12.76% -52.47%
157.2B
35.0B
-6.28% -28.38%
135.28
4.49
-26.40% -92.03%
88.0B
27.4B
4.20% -9.55%
181.67
3.21
1.51% -91.32%
19.1B
16.0B
0.53% 124.77%
-38.54
1.19
7.23% 71.10%
MID-CAP
4.2B
1.7B
3.02% -25.84%
9.71
2.44
54.01% 364.56%
3.5B
4.6B
-12.14% -24.54%
-456.23
0.77
-0.06% 94.55%
2.5B
9.0B
7.06% -6.96%
-5.5
0.28
10.01% -27.45%
2.0B
676.2M
-6.90% -30.70%
12.79
2.93
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-10.75% 3.11%
-3.65
1.73
24.65% 80.36%
21.9M
1.3M
-11.21% -52.08%
-2.96
16.83
-98.14% -104.71%
15.8M
89.6M
-10.58% -19.13%
-1.11
0.19
287.27% -129.41%
2.2M
21.5M
-15.79% -88.85%
-0.28
0.1
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Eagle Pharmaceuticals Inc-DE News

Latest updates
The Globe and Mail45 hours ago
The Globe and Mail06 Jun 202407:00 am

Eagle Pharmaceuticals Inc-DE Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-2.5%65.0066.0061.0066.0074.0011642.0040.0048.0041.0050.0050.0042.0046.0048.0041.0057.0050.0056.0051.0059.00
Costs and Expenses-0.3%54.0055.0051.0056.0072.0056.0036.0050.0037.0045.0040.0035.0038.0042.0045.0044.0047.0038.00---
Operating Expenses----------------44.0047.0038.0040.0033.0059.00
  S&GA Expenses-1.1%28.0028.0024.0023.0037.0022.0020.0018.0017.0020.0018.0018.0018.0025.0022.0019.0017.0018.0015.0014.0016.00
  R&D Expenses6.1%10.009.007.009.0011.006.004.0023.0010.0014.009.005.007.009.0011.0010.009.006.006.006.0015.00
EBITDA Margin87.6%0.14*0.07*0.21*0.18*0.16*0.22*-0.01*0.04*0.16*0.16*0.14*0.10*0.04*--------
Interest Expenses-4.5%1.002.002.001.001.000.000.000.000.000.000.000.001.001.001.001.001.001.001.001.001.00
Income Taxes-7.7%4.004.005.003.004.0014.007.00-7.042.002.003.002.006.00-0.142.00-0.152.003.003.004.00-3.18
Earnings Before Taxes-9.1%9.0010.0013.00-3.66-5.8758.001.00-12.666.001.0011.009.005.00-3.013.00-2.549.0012.0015.0018.00-0.52
EBT Margin116.0%0.11*0.05*0.19*0.17*0.15*0.21*-0.03*0.03*0.14*0.15*0.12*0.08*0.02*--------
Net Income-10.2%5.006.008.00-7.13-9.4544.00-6.20-5.624.00-0.428.007.00-0.26-2.871.00-2.397.009.0013.0014.003.00
Net Income Margin564.7%0.05*-0.01*0.11*0.07*0.08*0.15*-0.05*0.03*0.10*0.08*0.06*0.03*-0.03*--------
Free Cashflow99.6%-0.13-33.5738.00-13.2443.00-16.788.001.009.0010.0020.005.0021.00--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-2.3%405414406386382320254256264260253248257362255257262259239269274
  Current Assets-2.7%187192189185194240173172176164166164168276179180186182164198202
    Cash Equivalents-29.9%15.0022.0055.0015.0037.0070.0098.0010010910510390.0010820211011710810279.0091.00100
  Inventory-3.8%42.0044.0048.0064.0058.0025.0022.009.008.007.008.007.008.008.007.007.0012.0010.008.007.006.00
  Net PPE-9.2%1.001.001.001.001.002.002.002.002.002.002.002.002.002.002.002.002.002.002.003.003.00
  Goodwill0%45.0045.0045.0042.0043.0040.0040.0040.0040.0040.0040.0040.0040.0040.0040.0040.0040.0040.0040.0040.0040.00
Liabilities-10.8%15317117315514410477.0071.0069.0069.0067.0075.0073.0018075.00---78.00--
  Current Liabilities-11.4%87.0098.0011112210910274.0048.0045.0042.0038.0046.0040.0014639.0042.0052.0044.0040.0035.0048.00
  Long Term Debt-10.1%62.0069.0056.0026.0028.00--19.0021.0023.0025.0027.0029.0031.0034.0036.0036.0037.0038.0039.0040.00
    LT Debt, Current10.6%8.008.006.0035.0022.0024.0026.008.008.008.008.008.007.001165.005.005.005.006.005.006.00
    LT Debt, Non Current-10.1%62.0069.0056.0026.0028.00--19.0021.0023.0025.0027.0029.0031.0034.0036.0036.0037.0038.0039.0040.00
Shareholder's Equity3.8%252243234232238216176185195191186173184182179176172175161194186
  Retained Earnings4.4%12211711210311012076.0082.0088.0084.0084.0076.0069.0070.0073.0071.0074.0067.0058.0046.0032.00
  Additional Paid-In Capital1.1%374370366362358329326321316312305296291285279273267262256252245
Shares Outstanding0.2%13.0013.0013.0013.0013.0013.0013.0013.0013.0013.0013.0014.0014.00--------
Float-----413---437---514---677---704
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations99.6%-126-33,51237,557-13,23742,992-16,6118,0811,0678,59310,47819,7605,62720,9523,158-3,20110,61422,39226,18138,1083,6885,667
  Share Based Compensation-9.6%4,1924,6394,1193,5374,5004,2954,6824,0844,2816,5086,3214,7226,2417,4725,1835,6515,3825,7824,5704,4724,735
Cashflow From Investing100.0%-6.00-12,558-9.00-11,237-75,416-168-49.00-5.00115-5,384-170-20196.00-17,972-130-304-166-177-81.00-33.00-
Cashflow From Financing-150.7%-6,41112,6462,3893,296-536-11,358-10,114-10,038-5,220-3,020-6,116-23,958-114,851107,055-4,105-1,227-16,237-2,656-50,462-12,676-1,090
  Buy Backs----9,951-8,0538,6458,2712,8651,4327,00023,0004,0009992,961-15,000-50,47712,1093,516
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

EGRX Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 64,646$ 74,136$ 130,951$ 190,010
Operating expenses:    
Cost of product sales16,85821,17134,15846,347
Cost of royalty revenue02,49305,072
Research and development9,83311,43719,10517,545
Selling, general and administrative27,65136,83255,61159,014
Total operating expenses54,34271,933108,874127,978
Income from operations10,3042,20322,07762,032
Interest income195244407398
Interest expense(1,448)(552)(2,964)(918)
Other income (expense), net247(7,763)9(9,720)
Total other expense, net(1,006)(8,071)(2,548)(10,240)
Income (loss) before income tax provision9,298(5,868)19,52951,792
Income tax provision(4,134)(3,582)(8,615)(17,184)
Net income (loss)$ 5,164$ (9,450)$ 10,914$ 34,608
Earnings (loss) per share attributable to common stockholders:    
Basic (in dollars per share)$ 0.39$ (0.74)$ 0.83$ 2.71
Diluted (in dollars per share)$ 0.39$ (0.74)$ 0.83$ 2.67
Weighted average number of common shares outstanding:    
Basic (in shares)13,090,85212,836,11613,075,09012,773,727
Diluted (in shares)13,154,59912,836,11613,151,10712,951,788
Product sales, net    
Revenue:    
Total revenue$ 42,993$ 49,201$ 89,214$ 139,289
Royalty revenue    
Revenue:    
Total revenue$ 21,653$ 24,935$ 41,737$ 50,721

EGRX Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 15,354$ 55,321
Accounts receivable, net115,14072,439
Inventories42,48247,794
Prepaid expenses and other current assets14,27413,200
Total current assets187,250188,754
Property and equipment, net1,0131,168
Intangible assets, net107,406118,327
Goodwill45,03345,033
Deferred tax asset, net30,71527,146
Other assets33,40525,732
Total assets404,822406,160
Current liabilities:  
Accounts payable15,84318,993
Accrued expenses and other current liabilities62,49085,844
Short-term debt, net8,2976,250
Total current liabilities86,630111,087
Long-term debt, net61,89656,216
Other long-term liabilities4,2565,297
Total liabilities152,782172,600
Commitments and Contingencies
Stockholders' equity:  
Preferred stock, 1,500,000 shares authorized and no shares issued or outstanding as of June 30, 2023 and December 31, 202200
Common stock, $0.001 par value; 50,000,000 shares authorized; 17,647,390 and 17,569,375 shares issued as of June 30, 2023 and December 31, 2022, respectively1818
Additional paid in capital373,831366,265
Accumulated other comprehensive loss(1,112)(1,112)
Retained earnings122,418111,504
Treasury stock, at cost, 4,552,730 and 4,552,730 shares as of June 30, 2023 and December 31, 2022, respectively(243,115)(243,115)
Total stockholders' equity252,040233,560
Total liabilities and stockholders' equity$ 404,822$ 406,160
EGRX
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
 CEO
 WEBSITEeagleus.com
 INDUSTRYPharmaceuticals
 EMPLOYEES134

Eagle Pharmaceuticals Inc-DE Frequently Asked Questions


What is the ticker symbol for Eagle Pharmaceuticals Inc-DE? What does EGRX stand for in stocks?

EGRX is the stock ticker symbol of Eagle Pharmaceuticals Inc-DE. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eagle Pharmaceuticals Inc-DE (EGRX)?

As of Fri Jun 21 2024, market cap of Eagle Pharmaceuticals Inc-DE is 75.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EGRX stock?

You can check EGRX's fair value in chart for subscribers.

What is the fair value of EGRX stock?

You can check EGRX's fair value in chart for subscribers. The fair value of Eagle Pharmaceuticals Inc-DE is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eagle Pharmaceuticals Inc-DE is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EGRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eagle Pharmaceuticals Inc-DE a good stock to buy?

The fair value guage provides a quick view whether EGRX is over valued or under valued. Whether Eagle Pharmaceuticals Inc-DE is cheap or expensive depends on the assumptions which impact Eagle Pharmaceuticals Inc-DE's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EGRX.

What is Eagle Pharmaceuticals Inc-DE's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, EGRX's PE ratio (Price to Earnings) is 5.78 and Price to Sales (PS) ratio is 0.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EGRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eagle Pharmaceuticals Inc-DE's stock?

In the past 10 years, Eagle Pharmaceuticals Inc-DE has provided -0.107 (multiply by 100 for percentage) rate of return.